CD63, a universal marker of exosomes in combination with PD-L1, is known to cause a worse response to immunotherapy, and when applied to clinical specimens, it has demonstrated exceptional capabilities in diagnosing and staging lung cancer [61]. Here, CD63 is linked to lung carcinoma.